Neuralink Receives Approval for Human Trials of Brain Implant for Paralysis

Elon Musk's Neuralink received approval from an independent review board to recruit for its first human trial of a brain implant for paralysis. The study targets individuals with paralysis from cervical spinal cord injuries or ALS. The trial uses a robot to implant a brain-computer interface in the brain region for movement intention. Initial goal is to control a computer cursor or keyboard with thoughts. Neuralink negotiated with FDA for potentially lower number of patients due to safety concerns. Elon Musk envisions treating conditions like obesity, autism, depression, and schizophrenia. Even if safe, commercial clearance may take over a decade.

Elon Musk's Neuralink received approval from an independent review board to recruit for its first human trial of a brain implant for paralysis. The study targets individuals with paralysis from cervical spinal cord injuries or ALS. The trial uses a robot to implant a brain-computer interface in the brain region for movement intention. Initial goal is to control a computer cursor or keyboard with thoughts. Neuralink negotiated with FDA for potentially lower number of patients due to safety concerns. Elon Musk envisions treating conditions like obesity, autism, depression, and schizophrenia. Even if safe, commercial clearance may take over a decade.

Elon Musk's Neuralink received approval from an independent review board to recruit for its first human trial of a brain implant for paralysis. The study targets individuals with paralysis from cervical spinal cord injuries or ALS. The trial uses a robot to implant a brain-computer interface in the brain region for movement intention. Initial goal is to control a computer cursor or keyboard with thoughts. Neuralink negotiated with FDA for potentially lower number of patients due to safety concerns. Elon Musk envisions treating conditions like obesity, autism, depression, and schizophrenia. Even if safe, commercial clearance may take over a decade.

This story involves 1 source and may affect public understanding of health / technology.